High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
55.26M
+32.11%
-0.787
+9.38%
57.92M
+77.12%
-0.817
+0.88%
66.81M
+37.74%
-0.759
+1.14%
Estimates Revision
The market is revising No Change the revenue expectations for Rhythm Pharmaceuticals, Inc. (RYTM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.51%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+3.51%
In Past 3 Month
14 Analyst Rating
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 125.42 USD with a low forecast of 110.00 USD and a high forecast of 142.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.700
Low
110.00
Averages
125.42
High
142.00
Current: 105.700
Low
110.00
Averages
125.42
High
142.00
Citi
NULL -> Buy
initiated
$136
2025-11-25
Reason
Citi
Price Target
$136
2025-11-25
initiated
NULL -> Buy
Reason
Citi initiated coverage of Rhythm Pharmaceuticals with a Buy rating and $136 price target. The firm says Rhythm is a commercial-stage biotech developing therapies that target the MC4R pathway for rare neuroendocrine diseases. Citi sees a high probability of approval for Imcivree in acquired hypothalamic obesity into the FDA action date of March 20, 2026.
Canaccord
Whitney Ijem
Buy
maintain
$105 -> $114
2025-11-10
Reason
Canaccord
Whitney Ijem
Price Target
$105 -> $114
2025-11-10
maintain
Buy
Reason
Canaccord analyst Whitney Ijem raised the firm's price target on Rhythm Pharmaceuticals to $114 from $105 and keeps a Buy rating on the shares. The firm said following a relatively uneventful 3Q25 report, the company announced that the PDUFA data for aHO has been extended by 3months to March 20, 2026 from December 20, 2025 previously. Canaccord remains confident that the aHO indication will be approved by March 20, 206 given setmelanotide's strong efficacy and safety profile, and they agree with the company's sentiment that the extension will only give them time to be even more prepared for launch.
Oppenheimer
Oppenheimer
Outperform -> Perform
downgrade
2025-11-05
Reason
Oppenheimer
Oppenheimer
Price Target
2025-11-05
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Rhythm Pharmaceuticals to Perform from Outperform without a price target. The shares are up 92% year-to-date on the "outstanding" clinical results for Imcivree and daily oral bivamelagon in hypothalamic obesity in addition to continued global commercial execution, the analyst tells investors in a research note. However, the firm now believes next month's hypothalamic obesity label expansion is fully priced into the shares. In addition, this quarter's Prader-Willi readout "offers limited catalytic potential," says Oppenheimer.
BofA
Tazeen Ahmad
Buy
maintain
$122 -> $128
2025-10-22
Reason
BofA
Tazeen Ahmad
Price Target
$122 -> $128
2025-10-22
maintain
Buy
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on Rhythm Pharmaceuticals to $128 from $122 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Goldman Sachs
Corinne Johnson
Buy
downgrade
$157 -> $139
2025-10-17
Reason
Goldman Sachs
Corinne Johnson
Price Target
$157 -> $139
2025-10-17
downgrade
Buy
Reason
Goldman Sachs analyst Corinne Johnson lowered the firm's price target on Rhythm Pharmaceuticals to $139 from $157 and keeps a Buy rating on the shares.
Morgan Stanley
NULL
to
Overweight
upgrade
$122 -> $129
2025-10-16
Reason
Morgan Stanley
Price Target
$122 -> $129
2025-10-16
upgrade
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on Rhythm Pharmaceuticals to $129 from $122 and keeps an Overweight rating on the shares. The firm believes commercial experience in Bardet-Biedl syndrome sets the stage for "meaningful label expansion" in hypothalamic obesity later this year, noting that the company has an associated PDUFA deadline of December 20.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Rhythm Pharmaceuticals Inc (RYTM.O) is -34.68, compared to its 5-year average forward P/E of -12.77. For a more detailed relative valuation and DCF analysis to assess Rhythm Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.77
Current PE
-34.68
Overvalued PE
-3.70
Undervalued PE
-21.85
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-10.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.29
Undervalued EV/EBITDA
-21.46
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
51.04
Current PS
0.00
Overvalued PS
147.30
Undervalued PS
-45.23
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 288.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
RYTM News & Events
Events Timeline
(ET)
2025-11-10
07:41:40
Rhythm to Showcase Four Datasets at ObesityWeek
2025-11-07 (ET)
2025-11-07
07:35:06
Rhythm Reveals FDA Extension for IMCIVREE Review Process
2025-11-04 (ET)
2025-11-04
07:14:35
Rhythm Pharmaceuticals announces Q3 earnings per share of 82 cents, surpassing consensus estimate of 73 cents.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/169f9ae9450819cee6c262d81cb2ab0c7997743b95a97a6efa06f0936f4ec661.png)
Preview
6.5
00:10 AMBarron'sThe Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/barrons.png)
Preview
4.5
11-24Barron'sS&P 500 Futures Rise in Pre-Market Session; Centene and Millicom International Cellular Take the Lead
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-11BenzingaCanaccord Genuity Reaffirms Buy Rating on Rhythm Pharmaceuticals and Increases Price Target to $114
Sign Up For More News
People Also Watch
FAQ
What is Rhythm Pharmaceuticals Inc (RYTM) stock price today?
What is Rhythm Pharmaceuticals Inc (RYTM)'s business?
What is the price predicton of RYTM Stock?
What is Rhythm Pharmaceuticals Inc (RYTM)'s revenue for the last quarter?
What is Rhythm Pharmaceuticals Inc (RYTM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Rhythm Pharmaceuticals Inc (RYTM)'s fundamentals?
How many employees does Rhythm Pharmaceuticals Inc (RYTM). have?